MAPS PBC No Longer a Public Benefit Corporation

The Multidisciplinary Association for Psychedelic Studies (MAPS) has been admirably resistant to the pressures of the market economy for a long time. But the capital have won, again, and in a somewhat sad move, MAPS’s pharmaceutical arm, the MAPS Public Benefit Corporation, has now become a conventionally structured pharmacological company called Lykos Pharmaceutical.

Rick Doblin is 70

Rick Doblin just turned 70, and I am writing this blog post to share my appreciation and respect for this man. 

MDMA-Assisted Therapy — One step closer to FDA approval

MDMA-Assisted Therapy (MAT) is one step closer to becoming medically available. After an epic 36-year long journey, the MAPS Public Benefit Corporation has completed data collection for the Phase 3 study of MAT for PTSD. As of November 22, 2022, the data set has been locked and is now ready for statistical analysis.

“The Canadian Psychedelic Survey”

First large Canadain Psychedelic Survey sponsored by MAPS PBC, Psygen, and SABI Mind, in collaboration with academics from Johns Hopkins, UCLA, University of Alabama, University of Michigan, Cleveland Clinic, McMaster, McGill, and UBC.